Jan Grunewald

Company: AstraZeneca

Job title: Associate Director

Seminars:

Conjugation Chemistry, Targeted Delivery Beyond the Liver and the Surprising Breakthroughs of 2025: A Fireside Chat with Industry Innovators 1:30 pm

Join leading experts in oligonucleotide delivery for a forward-looking exploration of the chemistries and technologies driving next-generation RNA therapeutics. Opening with a focused, high-impact overview of state-of-the-art conjugation strategies across oligo modalities and expanding the conversation to discuss the broader evolution of delivery, from decades of liver-centric limitations to the emerging wave of extra-hepatic targeting. Together,…Read more

day: Conference Day Two

Leveraging Delivery Approaches to Translate Oligonucleotide-Based Therapies for Different Indications 9:05 am

The success of oligonucleotide therapeutics hinges not only on target selection and chemistry but also on delivery strategies that can unlock extrahepatic targets and expand the reach of these modalities. While conjugate-based approaches have driven remarkable progress in hepatocyte delivery, new indications, from neuromuscular diseases to oncology, demand innovative delivery solutions to overcome biological barriers,…Read more

day: Pre-Conference Workshop Day